+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Antitussive Drugs Market - Global Industry Size, Share, Trends Opportunity, and Forecast, 2028F

  • PDF Icon

    Report

  • 185 Pages
  • October 2023
  • Region: Global
  • TechSci Research
  • ID: 5900245
Free Webex Call
10% Free customization

Global Antitussive Drugs Market is Anticipated to Project Impressive Growth in the Forecast Period

Free Webex Call

Speak directly to the analyst to clarify any post sales queries you may have.

10% Free customization

This report comes with 10% free customization, enabling you to add data that meets your specific business needs.

Global Antitussive Drugs Market is anticipated to project impressive growth in the forecast period. The antitussive drugs market is a significant segment within the broader pharmaceutical industry, reflecting the high prevalence of respiratory conditions worldwide. Market growth is driven by factors such as the aging population, increasing pollution levels, and growing awareness of respiratory health.

Key Market Drivers

Respiratory Diseases and Infections

Respiratory diseases, such as asthma, chronic obstructive pulmonary disease (COPD), bronchitis, and pneumonia, are prevalent worldwide. These conditions often manifest with persistent coughing as a prominent symptom. The substantial and growing number of individuals affected by these respiratory ailments creates a significant patient pool in need of treatment, thereby driving the demand for antitussive drugs. Respiratory infections, including viral and bacterial infections like influenza and pneumonia, are widespread and can lead to severe bouts of coughing. Such infections are responsible for numerous doctor visits and hospitalizations. The recurrent nature of respiratory infections, especially during flu seasons, drives the demand for antitussive drugs as healthcare providers prescribe these medications to alleviate coughing and improve patient comfort.

Chronic respiratory diseases, which are often characterized by persistent coughing, significantly impact patients' quality of life. Coughing can disrupt sleep, hinder daily activities, and lead to social isolation. Antitussive drugs are prescribed to improve the overall well-being of patients by reducing the frequency and severity of coughing episodes. This aspect is particularly important for patients seeking relief and a better quality of life. Respiratory diseases and infections require effective management to prevent complications and hospitalizations. Antitussive drugs contribute to better symptom control and reduced coughing, which encourages patients to adhere to their treatment regimens. Improved patient compliance and adherence result in a more favorable prognosis, reduced healthcare costs, and ultimately, a higher demand for antitussive medications.

Chronic respiratory diseases and frequent respiratory infections can place a substantial economic burden on healthcare systems. Effective antitussive therapy can reduce the frequency of hospitalizations and emergency room visits, leading to cost savings. Healthcare providers and payers may opt for antitussive drugs as a cost-effective measure to manage coughing-related symptoms, which further drives market growth.

Changing Demographics and Aging Population

One of the most prominent factors contributing to the demand for antitussive drugs is the global increase in the elderly population. As a result of declining birth rates and extended life expectancy, there is a growing number of elderly individuals worldwide. Advanced age is associated with a higher likelihood of developing chronic respiratory conditions, which frequently lead to persistent coughing. Consequently, the aging demographic represents a substantial patient base requiring antitussive treatments. Aging is often accompanied by a greater susceptibility to respiratory diseases such as COPD, pneumonia, and bronchitis. These conditions are often characterized by chronic coughing, which can be debilitating for older individuals. As the elderly population continues to expand, the prevalence of age-related respiratory ailments is expected to rise, further fueling the demand for antitussive medications.

Elderly individuals frequently suffer from multiple comorbidities or chronic health conditions simultaneously. These comorbidities may necessitate the use of various medications, some of which can have coughing as a side effect. Antitussive drugs become essential in managing coughing as a side effect of other medications, promoting patient comfort, and ensuring better overall health management. Many countries have prioritized improving healthcare access for their aging populations. This includes programs like Medicare in the United States, which ensures that seniors have access to essential healthcare services and medications. The availability of healthcare coverage for seniors encourages them to seek treatment for respiratory symptoms and coughing, leading to increased prescription rates for antitussive drugs.

The ongoing advancements in healthcare and medical technologies have led to improved life expectancy. As people live longer, they are more likely to encounter age-related health issues, including respiratory problems. The longer lifespan of individuals contributes to the sustained demand for antitussive drugs as a means to manage coughing associated with aging and age-related health conditions.

Increasing Pollution Levels

Increasing pollution levels serve as a compelling market driver for the global antitussive drugs market. The rise in environmental pollution, particularly air pollution, has a direct impact on respiratory health and contributes to the growing demand for antitussive medications. Escalating industrialization, urbanization, and vehicular emissions have led to deteriorating air quality in many regions across the globe. Pollutants such as particulate matter (PM), ozone, and nitrogen dioxide irritate the respiratory system, triggering coughing and exacerbating underlying respiratory conditions. The prevalence of poor air quality conditions necessitates the use of antitussive drugs to manage persistent coughing symptoms, driving up demand.

Individuals exposed to high levels of air pollution are more likely to experience respiratory symptoms, including coughing, throat irritation, and shortness of breath. These symptoms prompt affected individuals to seek medical attention. Healthcare providers often prescribe antitussive drugs to alleviate coughing, making them a common therapeutic choice in regions with significant pollution concerns.

Air pollution can exacerbate preexisting respiratory conditions, such as asthma and chronic obstructive pulmonary disease (COPD). These individuals experience more frequent and severe coughing episodes. The need for effective management of coughing in patients with compromised respiratory health drives the demand for antitussive medications, creating a market opportunity.

Poor air quality contributes to an uptick in healthcare utilization, leading to higher healthcare costs. Hospitalizations and emergency room visits due to respiratory issues become more common in areas with severe pollution. The adoption of antitussive drugs can help mitigate the severity of coughing episodes, potentially reducing the frequency of hospitalizations and associated healthcare expenses, making them an attractive option from a cost-saving perspective.

Consumer Awareness and Accessibility

Consumer awareness and accessibility are crucial market drivers for the global antitussive drugs market. These drivers are intertwined and encompass various factors that influence the demand for antitussive medications. Growing consumer awareness of health and wellness has led individuals to seek medical advice and treatment for persistent coughing and respiratory symptoms. Informed consumers are more likely to recognize the potential benefits of antitussive drugs in alleviating coughing, leading to higher demand for these medications.

Consumers today are more inclined to self-diagnose and manage minor health issues. Over the counter (OTC) antitussive drugs are readily available in pharmacies and retail outlets. Accessibility to OTC antitussive medications empowers consumers to take control of their health, making these products a convenient choice for managing coughing. Pharmaceutical companies invest significantly in marketing and advertising campaigns to raise awareness about their antitussive products. Direct-to-consumer advertising informs potential users about the benefits of these drugs. Effective marketing strategies contribute to consumer awareness and encourage individuals to discuss antitussive options with healthcare providers.

Accessibility to healthcare services and medications, including antitussive drugs, is influenced by economic factors. The affordability of these drugs is a crucial consideration for consumers. The availability of generic antitussive medications and cost-effective treatment options ensures that a broader spectrum of the population can access and afford these drugs.

The internet has become a valuable source of health information for consumers. Online resources, medical websites, and social media platforms provide information about common health issues, including coughing and its management. Consumers can research antitussive drugs and their effectiveness, leading to informed discussions with healthcare professionals and increased demand for these products.

Key Market Challenges

Regulatory Hurdles and Stringent Approvals

One of the primary challenges in the antitussive drugs market is the rigorous regulatory environment governing pharmaceuticals. To ensure safety and efficacy, regulatory agencies such as the FDA (U.S. Food and Drug Administration) and the EMA (European Medicines Agency) impose stringent approval processes for new antitussive drugs.

Developing and bringing a new antitussive drug to market involves extensive clinical trials, data submission, and regulatory reviews. The process is time-consuming and costly, with no guarantee of approval. Companies may face delays, increased development costs, or even the rejection of their drug candidates, impacting market entry.

Increasing Competition and Generic Substitution

The antitussive drugs market has witnessed growing competition from both established pharmaceutical companies and generic drug manufacturers. As patents for branded antitussive medications expire, generic versions become available, leading to price erosion and market share challenges.

Generic substitution, driven by cost-conscious healthcare systems and insurers, can significantly impact the revenue and profitability of branded antitussive drugs. Manufacturers of branded products must compete aggressively to retain market share, often leading to price wars and decreased profit margins.

Evolving Healthcare Trends and Non-Pharmacological Approaches

Healthcare trends are shifting toward preventive medicine, holistic care, and non-pharmacological interventions. Patients and healthcare providers increasingly seek alternatives to drug therapy for managing coughing and respiratory symptoms.

Lifestyle modifications, dietary changes, and the adoption of healthier habits are promoted as ways to address coughing issues without resorting to antitussive drugs. This trend challenges the market's growth by reducing the reliance on pharmaceutical solutions.

Key Market Trends

Shift Towards Non-Opioid and Non-Codeine Formulations

One of the prominent trends in the antitussive drugs market is the increasing preference for non-opioid and non-codeine formulations. This shift is primarily driven by concerns related to the addictive potential and side effects associated with opioid-based antitussive drugs.

Regulatory Scrutiny: Regulatory agencies like the FDA have imposed stricter controls and monitoring of opioid-based medications due to their potential for abuse and addiction. This has led to a reduced appetite among healthcare providers to prescribe such drugs. Patient Safety: Patient safety and minimizing the risk of opioid misuse have become paramount concerns. Non-opioid alternatives are seen as safer options for managing coughing, especially in pediatric and vulnerable patient populations.

Advances in pharmaceutical research have led to the development of non-opioid antitussive medications that offer comparable efficacy in suppressing coughing without the risk of opioid-related complications. This has fueled the market demand for non-opioid alternatives.

Growing Interest in Combination Therapies

Another significant trend in the antitussive drugs market is the emergence of combination therapies. These formulations combine antitussive agents with other active ingredients to address multiple symptoms simultaneously, such as coughing, congestion, and pain.

Enhanced Symptom Relief: Patients often experience multiple symptoms, such as a cough accompanied by congestion or sore throat. Combination therapies offer comprehensive relief, reducing the need for multiple medications. Improved Patient Compliance: Simplifying treatment regimens by combining drugs into a single dosage form can enhance patient compliance, leading to better treatment outcomes.

Pharmaceutical companies aim to differentiate their products by offering innovative combination therapies that cater to a broader range of patient needs. This trend creates opportunities for product innovation and market growth.

Rise in Telehealth and E-Pharmacy Services

The adoption of telehealth and e-pharmacy services has witnessed significant growth, and this trend is influencing the antitussive drugs market. Patients are increasingly consulting healthcare providers remotely and obtaining prescriptions through online platforms.

Telehealth and e-pharmacy services offer patients a convenient and accessible way to seek medical advice, including for managing coughing and respiratory symptoms. Pandemic-Induced Shift: The COVID-19 pandemic accelerated the adoption of telehealth, and many patients have continued to embrace these virtual healthcare options even as pandemic restrictions eased. Patients can receive electronic prescriptions for antitussive drugs through telehealth consultations and have them filled at e-pharmacies, making the process seamless and efficient.

Segmental Insights

Drug Class Insights

Based on the category of Drug Class, the peripherally acting drugs segment emerged as the dominant player in the global market for Antitussive Drugs in 2022. Peripherally acting drugs have become dominant in the global antitussive drug market due to several factors that enhance their effectiveness, safety, and market appeal. Peripherally acting antitussive drugs primarily target the cough reflex at the level of the peripheral nervous system or the respiratory tract. Peripherally acting antitussive drugs typically do not exert their effects on the central nervous system (CNS) to the same extent as centrally acting drugs, particularly opioids.

This reduced central nervous system penetration results in a lower risk of side effects like drowsiness, sedation, and dependence, making peripherally acting drugs a safer option for a broader patient population. Many peripherally acting antitussive drugs do not contain opioids, which have faced increasing scrutiny due to their potential for abuse and addiction. Non-opioid antitussive options align with evolving healthcare trends focused on minimizing opioid usage, especially in cases where alternatives are available.

Peripherally acting antitussive drugs have been developed to specifically target the underlying causes of coughing, such as irritation in the airways or increased mucus production. By directly addressing the physiological mechanisms that trigger coughing, these drugs provide effective cough suppression without the sedating effects often associated with centrally acting antitussives. These factors are expected to drive the growth of this segment.

Route of Administration Insight

Based on the category of Route of Administration, the oral segment emerged as the dominant player in the global market for Antitussive Drugs in 2022. The dominance of the oral route of administration in the global antitussive drug market can be attributed to several factors that make it the preferred method for delivering these medications. The oral route, which includes tablets, capsules, syrups, and liquids, offers advantages in terms of convenience, patient compliance, and ease of administration. Oral antitussive medications are generally considered more patient-friendly and convenient compared to other routes of administration, such as inhalation or injection.

Patients can take oral medications at home without the need for medical supervision, making them accessible and user-friendly. Administering oral antitussive drugs is straightforward and does not require specialized training or equipment. Patients can simply swallow a tablet or take a liquid medication with a measuring cup or spoon. This ease of administration makes oral antitussives suitable for a wide range of patients, including children and the elderly.

Oral medications are often associated with high levels of patient compliance because they are easy to administer and integrate into daily routines. Patients are more likely to adhere to their treatment regimens when the medication is administered orally, which contributes to better treatment outcomes. These factors are expected to drive the growth of this segment.

Age Group Insight

Based on the category of Age Group, the adult segment emerged as the dominant player in the global market for Antitussive Drugs in 2022. The dominance of the adult age group segment in the global antitussive drug market can be attributed to several factors related to the prevalence of coughing and respiratory conditions, the suitability of certain medications for adults, and evolving healthcare trends. Adults generally have a higher prevalence of respiratory conditions such as chronic obstructive pulmonary disease (COPD), asthma, and bronchitis compared to children and infants.

These conditions often lead to chronic coughing, which necessitates the use of antitussive drugs for symptom management, contributing to the dominance of the adult segment.

Adults are more likely to be exposed to environmental factors such as pollution, smoking, and workplace irritants that can trigger coughing and exacerbate respiratory conditions. Lifestyle factors, including smoking habits, place adults at a higher risk of developing cough-related issues, making antitussive drugs a common treatment choice.

Some antitussive medications are specifically formulated and tested for adult use, taking into consideration factors such as metabolism, body weight, and physiological differences. These formulations are often optimized for adults, ensuring that they are effective in suppressing coughing and addressing the unique needs of this age group. These factors are expected to drive the growth of this segment.

End-User Insights

The homecare segment is projected to experience rapid growth during the forecast period. Homecare offers patients the convenience and comfort of managing cough and respiratory symptoms in a familiar and relaxed environment.Patients often prefer the comfort of their homes over hospitals or clinics, especially when dealing with mild to moderate coughing episodes.

Homecare empowers patients to take an active role in managing their health. Patients can self-administer antitussive drugs as prescribed, fostering a sense of control over their treatment. Self-management aligns with evolving healthcare trends that emphasize patient autonomy and involvement in healthcare decisions.

Homecare is generally more cost-effective than hospital or clinic-based care. Patients can avoid the expenses associated with hospital stays, consultations, and transportation. The cost savings associated with homecare make it an attractive option for both patients and healthcare systems. These factors collectively contribute to the growth of this segment.

Regional Insights

North America emerged as the dominant player in the global Antitussive Drugs market in 2022, holding the largest market share in terms of value. The United States and Canada has been a dominant region in the global antitussive drugs market. Reasons for dominance include a large population, a high prevalence of respiratory conditions like asthma and chronic obstructive pulmonary disease (COPD), and a well-developed healthcare infrastructure. The region's strong pharmaceutical industry, coupled with a high level of healthcare expenditure, has contributed to the prominence of North America in the market.

The Asia-Pacific market is poised to be the fastest-growing market, offering lucrative growth opportunities for Antitussive Drugs players during the forecast period. Factors such as The Asia-Pacific region is home to a significant portion of the world's population, including a growing elderly demographic. Aging populations are more susceptible to respiratory conditions, including chronic coughing, which drives the demand for antitussive medications. Rapid industrialization, urbanization, and environmental pollution have led to a rise in respiratory health concerns in many Asia-Pacific countries. Poor air quality, exacerbated by pollution, contributes to higher incidences of respiratory conditions and coughing, necessitating the use of antitussive drugs. Improvements in healthcare access and awareness in the Asia-Pacific region have led to earlier diagnosis and treatment of respiratory conditions. Patients and healthcare providers have become more aware of the importance of managing coughing and related symptoms, driving the demand for antitussive drugs.

Report Scope:

In this report, the Global Antitussive Drugs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Antitussive Drugs Market, By Drug Class:

  • Peripherally Acting Drugs
  • Centrally Acting Drugs
  • Others

Antitussive Drugs Market, By Route of Administration:

  • Inhalational
  • Oral
  • Others

Antitussive Drugs Market, By Age Group:

  • Geriatric
  • Pediatric
  • Adult

Antitussive Drugs Market, By End-User:

  • Homecare
  • Hospitals & Specialty Clinics
  • Others

Antitussive Drugs Market, By Region:

  • North America
  • United States
  • Canada
  • Mexico
  • Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
  • Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • South America
  • Brazil
  • Argentina
  • Colombia
  • Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait
  • Turkey
  • Egypt

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Antitussive Drugs Market.

Available Customizations:

Global Antitussive Drugs market report with the given market data, the publisher offers customizations according to a company's specific needs.


This product will be delivered within 1-3 business days.

Table of Contents

1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Age Groups
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. Voice of Customer
5. Global Antitussive Drugs Market Outlook
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Drug Class (Peripherally Acting Drugs, Centrally Acting Drugs, Others)
5.2.2. By Route of Administration (Inhalational, Oral, Others)
5.2.3. By Age Group (Geriatric, Pediatric, Adult)
5.2.4. By End-User (Homecare, Hospitals & Specialty Clinics, Others)
5.2.5. By Region
5.2.6. By Company (2022)
5.3. Market Map
6. North America Antitussive Drugs Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Drug Class
6.2.2. By Route of Administration
6.2.3. By Age Group
6.2.4. By End-User
6.2.5. By Country
6.3. North America: Country Analysis
6.3.1. United States Antitussive Drugs Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Drug Class
6.3.1.2.2. By Route of Administration
6.3.1.2.3. By Age Group
6.3.1.2.4. By End-User
6.3.2. Canada Antitussive Drugs Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Drug Class
6.3.2.2.2. By Route of Administration
6.3.2.2.3. By Age Group
6.3.2.2.4. By End-User
6.3.3. Mexico Antitussive Drugs Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Drug Class
6.3.3.2.2. By Route of Administration
6.3.3.2.3. By Age Group
6.3.3.2.4. By End-User
7. Europe Antitussive Drugs Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Drug Class
7.2.2. By Route of Administration
7.2.3. By Age Group
7.2.4. By End-User
7.3. Europe: Country Analysis
7.3.1. Germany Antitussive Drugs Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Drug Class
7.3.1.2.2. By Route of Administration
7.3.1.2.3. By Age Group
7.3.1.2.4. By End-User
7.3.2. United Kingdom Antitussive Drugs Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Drug Class
7.3.2.2.2. By Route of Administration
7.3.2.2.3. By Age Group
7.3.2.2.4. By End-User
7.3.3. Italy Antitussive Drugs Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecasty
7.3.3.2.1. By Drug Class
7.3.3.2.2. By Route of Administration
7.3.3.2.3. By Age Group
7.3.3.2.4. By End-User
7.3.4. France Antitussive Drugs Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Drug Class
7.3.4.2.2. By Route of Administration
7.3.4.2.3. By Age Group
7.3.4.2.4. By End-User
7.3.5. Spain Antitussive Drugs Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Drug Class
7.3.5.2.2. By Route of Administration
7.3.5.2.3. By Age Group
7.3.5.2.4. By End-User
8. Asia-Pacific Antitussive Drugs Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Drug Class
8.2.2. By Route of Administration
8.2.3. By Age Group
8.2.4. By End-User
8.3. Asia-Pacific: Country Analysis
8.3.1. China Antitussive Drugs Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Drug Class
8.3.1.2.2. By Route of Administration
8.3.1.2.3. By Age Group
8.3.1.2.4. By End-User
8.3.2. India Antitussive Drugs Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Drug Class
8.3.2.2.2. By Route of Administration
8.3.2.2.3. By Age Group
8.3.2.2.4. By End-User
8.3.3. Japan Antitussive Drugs Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Drug Class
8.3.3.2.2. By Route of Administration
8.3.3.2.3. By Age Group
8.3.3.2.4. By End-User
8.3.4. South Korea Antitussive Drugs Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Drug Class
8.3.4.2.2. By Route of Administration
8.3.4.2.3. By Age Group
8.3.4.2.4. By End-User
8.3.5. Australia Antitussive Drugs Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Drug Class
8.3.5.2.2. By Route of Administration
8.3.5.2.3. By Age Group
8.3.5.2.4. By End-User
9. South America Antitussive Drugs Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Drug Class
9.2.2. By Route of Administration
9.2.3. By Age Group
9.2.4. By End-User
9.3. South America: Country Analysis
9.3.1. Brazil Antitussive Drugs Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Drug Class
9.3.1.2.2. By Route of Administration
9.3.1.2.3. By Age Group
9.3.1.2.4. By End-User
9.3.2. Argentina Antitussive Drugs Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Drug Class
9.3.2.2.2. By Route of Administration
9.3.2.2.3. By Age Group
9.3.2.2.4. By End-User
9.3.3. Colombia Antitussive Drugs Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Drug Class
9.3.3.2.2. By Route of Administration
9.3.3.2.3. By Age Group
9.3.3.2.4. By End-User
10. Middle East and Africa Antitussive Drugs Market Outlook
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Drug Class
10.2.2. By Route of Administration
10.2.3. By Age Group
10.2.4. By End-User
10.3. MEA: Country Analysis
10.3.1. South Africa Antitussive Drugs Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Drug Class
10.3.1.2.2. By Route of Administration
10.3.1.2.3. By Age Group
10.3.1.2.4. By End-User
10.3.2. Saudi Arabia Antitussive Drugs Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Drug Class
10.3.2.2.2. By Route of Administration
10.3.2.2.3. By Age Group
10.3.2.2.4. By End-User
10.3.3. UAE Antitussive Drugs Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Drug Class
10.3.3.2.2. By Route of Administration
10.3.3.2.3. By Age Group
10.3.3.2.4. By End-User
11. Market Dynamics
11.1. Drivers & Challenges
12. Market Trends & Developments
12.1. Recent Developments
12.2. Product Launches
12.3. Mergers & Acquisitions
13. Global Antitussive Drugs Market: SWOT Analysis
14. Competitive Landscape
14.1. Teva Pharmaceutical Industries Ltd.
14.2. Intas Pharmaceuticals Ltd.
14.3. Bayer AG
14.4. Ipca Laboratories Ltd.
14.5. F. Hoffmann-La Roche Ltd.
14.6. Hikma Pharmaceuticals PLC
14.7. Unique Pharmaceuticals Limited
14.8. Cipla Inc.
14.9. Mylan N.V.
14.10. Aurobindo Pharma
15. Strategic Recommendations16. About the Publisher & Disclaimer

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Teva Pharmaceutical Industries Ltd.
  • Intas Pharmaceuticals Ltd.
  • Bayer AG
  • Ipca Laboratories Ltd.
  • F. Hoffmann-La Roche Ltd.
  • Hikma Pharmaceuticals PLC
  • Unique Pharmaceuticals Limited
  • Cipla Inc.
  • Mylan N.V.
  • Aurobindo Pharma